Radical immune 'Reset' tested as potential lifeline for Tough-to-Treat lupus
NCT ID NCT07328581
Summary
This early-stage study is testing a new type of cell therapy called ICG318 for people with severe, hard-to-treat systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove the faulty B cells thought to drive lupus. The main goals are to see if the treatment is safe and if it can put the disease into remission without the need for ongoing lupus medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.